Plant Compound Shows Promise Against Antibiotic-Resistant Bacteria
Similar Articles
Researchers Identify Enzymes for Production of Rare Plant Compound Mitraphylline
Brazilian Tree Compounds Show Activity Against SARS-CoV-2
New Drugs Target 'Zombie' Cells to Combat Cancer and Aging
Engineered Algae Could Filter Microplastics from Water
Graphene Oxide's Antibacterial Mechanism Identified, Paving Way for Medical and Textile Applications
A plant-derived compound, madecassic acid, has been shown to stop the growth of antibiotic-resistant E. coli by targeting a bacterial protein system not found in humans. Researchers modified the compound to enhance its effectiveness, with one version killing the bacteria at higher concentrations. This discovery offers a potential new pathway for developing antibiotics to combat antimicrobial resistance.
Facts First
- Madecassic acid can stop the growth of antibiotic-resistant E. coli by binding to a bacterial protein system.
- The compound targets the cytochrome bd complex, a system bacteria use for respiration that is not present in humans or animals.
- Researchers created three modified versions of the compound, all of which successfully blocked the bacterial complex.
- One modified version killed E. coli at higher concentrations.
- Antimicrobial resistance is a major global threat, with estimates of 39 million deaths from 2025 to 2050.
What Happened
Scientists from the University of Kent and University College London (UCL) found that madecassic acid can stop the growth of antibiotic-resistant E. coli. Using computer-based screening and laboratory experiments, they found the compound works by binding to the cytochrome bd complex, a protein system bacteria use for respiration during infection. Researchers extracted the compound from a plant sample in Vietnam and created three modified versions of its chemical structure, all of which successfully blocked the bacterial complex and halted growth. One modified version killed E. coli at higher concentrations.
Why this Matters to You
Antimicrobial resistance is a growing threat to public health, with experts estimating it could lead to 39 million deaths between 2025 and 2050. This discovery could lead to the development of new antibiotics that work differently from current ones, potentially restoring treatment options for serious bacterial infections. Because the compound targets a bacterial system not found in humans or animals, future drugs based on this research might have fewer side effects.
What's Next
The modified versions of madecassic acid will likely undergo further laboratory testing to understand their full potential and safety profile. This research may open a new pathway for drug development, but any resulting antibiotic would still need to go through years of clinical trials before becoming available.